REMS Safety Program for Esketamine in Treatment-Resistant Depression
Steven Levine, MD: Let us move on to discussing the practical considerations of delivering esketamine to patients and integrating this into patient care. Let us start with Angelos. Can you speak to the idea that intranasal esketamine has a risk evaluation and mitigation strategy [REMS]? Angelos Halaris, MD, PhD, APA, ACNP, CINP: Absolutely. As I […]
REMS Safety Program for Esketamine in Treatment-Resistant Depression Read More »